Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
1.050
+0.020 (1.94%)
At close: Aug 13, 2025, 4:00 PM
1.050
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:58 AM EDT
Aditxt Revenue
Aditxt had revenue of $1.02K in the quarter ending March 31, 2025, a decrease of -98.72%. This brings the company's revenue in the last twelve months to $55.32K, down -89.08% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$55.32K
Revenue Growth
-89.08%
P/S Ratio
3.59
Revenue / Employee
$2,128
Employees
26
Market Cap
5.20M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADTX News
- 3 days ago - Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative - Business Wire
- 9 days ago - Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference - PRNewsWire
- 16 days ago - Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases - Business Wire
- 21 days ago - Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test - Business Wire
- 23 days ago - Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET - Business Wire
- 4 weeks ago - Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy - PRNewsWire
- 5 weeks ago - Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization - Business Wire
- 7 weeks ago - Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET - Business Wire